ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Clinical and MRI factors influencing interobserver delineation variability of brain metastases before stereotactic radiotherapy.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInnovations in systemic therapies have prolonged survival for many cancers, increasing the number of patients living with brain metastases. In stereotactic radiotherapy, steep dose gradients and small target margins mean that delineation differences may affect target coverage and the dose to adjacent normal brain. We aimed to identify lesion- and MRI-related factors associated with interobserver variability in brain metastasis gross tumor volume delineation.
methodsWe retrospectively included 149 patients (354 metastases) treated with stereotactic radiotherapy at the University Hospital of Brest (2014-2022). Four radiology residents delineated each metastasis on pretreatment three-dimensional T1-weighted gadolinium-enhanced MRI after completing a structured training set of 40 brain metastases selected outside the study cohort (excluded from all analyses). Lesion characteristics (edema, hemorrhage, necrosis/cystic change, proximity to organs at risk, histology, and volume) and MRI acquisition parameters were collected. Interobserver agreement was quantified using the Dice similarity coefficient and the mean distance to agreement (MDA).
resultsMedians and interquartile ranges (IQRs) for Dice and MDAs across metastases (pairwise values averaged per metastasis) were 0.85 (IQR 0.80-0.89) and 0.34 mm (IQR 0.29-0.44), respectively. Lesions with perilesional edema and a larger volume showed higher overlap agreement (Dice); however, MDA increased with lesion volume, consistent with greater absolute boundary deviations in larger lesions. Several distance-to-OAR variables showed significant univariable associations with agreement metrics; however, these findings were inconsistent across Dice and MDA and were not retained in multivariable analysis. Among MRI parameters, 3 T field strength was associated with a slightly higher agreement; no other parameters showed consistent associations in this exploratory analysis.
conclusionInterobserver variability in brain metastasis delineation varies with lesion characteristics and selected MRI acquisition parameters. Standardized contouring guidance and MRI acquisition may reduce variability, supporting quality assurance and peer-review processes for stereotactic radiotherapy.
Indexed as
Identifiers
42446590What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.